相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PCV13 Vaccination of Adults against Pneumococcal Disease: What We Have Learned from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)
Christian Theilacker et al.
MICROORGANISMS (2022)
Comparison of PCV-10 and PCV-13 vaccine coverage for invasive pneumococcal isolates obtained across Canadian geographic regions, SAVE 2011 to 2017
Rachel K. Hink et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2021)
Pneumococcal Conjugate Vaccine Impact on Serotype 3: A Review of Surveillance Data
Heather L. Sings et al.
INFECTIOUS DISEASES AND THERAPY (2021)
The Evolution and Distribution of Pneumococcal Serotypes in Adults Hospitalized With Community-Acquired Pneumonia in Spain Using a Serotype-Specific Urinary Antigen Detection Test: The CAPA Study, 2011-2018
Antoni Torres et al.
CLINICAL INFECTIOUS DISEASES (2021)
Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-acquired Pneumonia in Hospitalized US Adults
Raul Isturiz et al.
CLINICAL INFECTIOUS DISEASES (2021)
Invasive pneumococcal disease in Canada 2010-2017: The role of current and next-generation higher-valent pneumococcal conjugate vaccines
Stephane B. Dion et al.
VACCINE (2021)
Whole Genome Analysis of Streptococcus pneumoniae Serotype 4 Causing Outbreak of Invasive Pneumococcal Disease, Alberta, Canada
James D. Kellner et al.
EMERGING INFECTIOUS DISEASES (2021)
Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013-18
Harry Pick et al.
THORAX (2020)
Pneumococcal conjugate serotype distribution and predominating role of serotype 3 in German adults with community-acquired pneumonia
Christina Forstner et al.
VACCINE (2020)
Qualification and Clinical Validation of an Immunodiagnostic Assay for Detecting 11 Additional Streptococcus pneumoniae Serotype-specific Polysaccharides in Human Urine
Warren Kalina et al.
CLINICAL INFECTIOUS DISEASES (2020)
Estimating Serotype-specific Efficacy of Pneumococcal Conjugate Vaccines Using Hierarchical Models
Joshua L. Warren et al.
EPIDEMIOLOGY (2020)
Routine infant vaccination of pneumococcal conjugate vaccines has decreased pneumonia across all age groups in Northern Spain
I Rivero-Calle et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2020)
Non-bacteremic pneumococcal pneumonia: general characteristics and early predictive factors for poor outcome
Leyre Serrano et al.
INFECTIOUS DISEASES (2020)
Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency
Alessandra Lochen et al.
SCIENTIFIC REPORTS (2020)
Cost-Effectiveness of Pneumococcal Vaccination and Uptake Improvement Programs in Underserved and General Population Adults Aged<65 Years
Angela R. Wateska et al.
JOURNAL OF COMMUNITY HEALTH (2020)
Age-stratified burden of pneumococcal community acquired pneumonia in hospitalised Canadian adults from 2010 to 2015
Jason LeBlanc et al.
BMJ OPEN RESPIRATORY RESEARCH (2020)
Decline in Pneumococcal Disease Attenuated in Older Adults and Those With Comorbidities Following Universal Childhood PCV13 Immunization
Stephen I. Pelton et al.
CLINICAL INFECTIOUS DISEASES (2019)
Limited indirect effects of an infant pneumococcal vaccination program in an aging population
Mark van der Linden et al.
PLOS ONE (2019)
Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN)
Jason J. LeBlanc et al.
VACCINE (2019)
A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands
Bradford D. Gessner et al.
VACCINE (2019)
Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults
Allison Thompson et al.
VACCINE (2019)
Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis
John M. McLaughlin et al.
VACCINE (2019)
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices
Almea Matanock et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2019)
An intervention to improve pneumococcal vaccination uptake in high risk 50-64 year olds vs. expanded age-based recommendations: an exploratory cost-effectiveness analysis
Angela R. Wateska et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)
The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007-2017
Shinthuja Wijayasri et al.
PLOS ONE (2019)
Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design
John M. McLaughlin et al.
CLINICAL INFECTIOUS DISEASES (2018)
Pneumococcal Community-Acquired Pneumonia Detected by Serotype-Specific Urinary Antigen Detection Assays
Richard G. Wunderink et al.
CLINICAL INFECTIOUS DISEASES (2018)
Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review
Antoni Torres et al.
RESPIRATORY MEDICINE (2018)
13-Valent vaccine serotype pneumococcal community acquired pneumonia in adults, in high clinical risk groups
Priya Daniel et al.
VACCINE (2018)
Serotype distribution of invasive Streptococcus pneumoniae in adults 65 years of age and over after the introduction of childhood 13-valent pneumococcal conjugate vaccination programs in Canada, 2010-2016
Walter H. B. Demczuk et al.
VACCINE (2018)
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults >= 50 years of age
Susan J. Ermlich et al.
VACCINE (2018)
Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium
Lander Willem et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)
Distribution of 13-Valent pneumococcal conjugate vaccine serotype streptococcus pneumoniae in adults 50Years and Older presenting with community-acquired pneumonia in Israel
Gili Regev-Yochay et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)
Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults
Mark Atwood et al.
CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE (2018)
The Importance of Frailty in the Assessment of Influenza Vaccine Effectiveness Against Influenza-Related Hospitalization in Elderly People
Melissa K. Andrew et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
Burden of vaccine-preventable pneumococcal disease in hospitalized adults: A Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) network study
Jason J. LeBlanc et al.
VACCINE (2017)
The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study
Rosario Menendez et al.
VACCINE (2017)
Rates and risk factors associated with hospitalization for pneumonia with ICU admission among adults
Aaron D. Storms et al.
BMC PULMONARY MEDICINE (2017)
Whole genome sequencing of Streptococcus pneumoniae: development, evaluation and verification of targets for serogroup and serotype prediction using an automated pipeline
Georgia Kapatai et al.
PEERJ (2016)
Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia
Chamira Rodrigo et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Detection and prediction of Streptococcus pneumoniae serotypes directly from nasopharyngeal swabs using PCR
Amanda L. S. Lang et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2015)
Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults
M. J. M. Bonten et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Community-Acquired Pneumonia Requiring Hospitalization among US Adults
S. Jain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Bacteraemic and non-bacteraemic/urinary antigen-positive pneumococcal community-acquired pneumonia compared
S. P. van Mens et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2015)
Recommendations for Pneumococcal Immunization Outside Routine Childhood Immunization Programs in Western Europe
Paolo Castiglia
ADVANCES IN THERAPY (2014)
Distribution of 13-Valent Pneumococcal Conjugate Vaccine Streptococcus pneumoniae Serotypes in US Adults Aged ≥50 Years With Community-Acquired Pneumonia
Robert L. Sherwin et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Estimating the Burden of Pneumococcal Pneumonia among Adults: A Systematic Review and Meta-Analysis of Diagnostic Techniques
Maria A. Said et al.
PLOS ONE (2013)
Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011
Wallis Rudnick et al.
VACCINE (2013)
Validation of an Immunodiagnostic Assay for Detection of 13 Streptococcus pneumoniae Serotype-Specific Polysaccharides in Human Urine
Michael W. Pride et al.
CLINICAL AND VACCINE IMMUNOLOGY (2012)
Healthcare utilization and cost of pneumococcal disease in the United States
Susan S. Huang et al.
VACCINE (2011)
分享论文
